Third Rock Ventures Sells $17.1M in Rapport Therapeutics Stock

Third Rock Ventures has sold $17.1 million worth of stock in Rapport Therapeutics. This transaction reflects changes in their investment strategy and may impact Rapport Therapeutics (not publicly traded) by affecting its capital structure and investor sentiment. The sale represents a significant divestment, which could be seen as a shift in confidence in the company's future prospects. Market participants will monitor such moves closely as they can influence share prices and investment dynamics.